## Tobacco Safety and Efficacy References for the Tobacco Treatment Guide

- 1. Fiore MC, Jaen CR, Baker TB, et al. Treatment Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008.
- Jamal A, Dube SR, Marlarcher AM, Shaw L, and Engstrom MC. Tobacco Use Screening and Counseling During Physician Office Visits Among Adults – National Ambulatory Medical Care Survey and National Health Interview Survey, United States, 2005-2009. MMWR 2012;60(02):38-45.
- 3. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological Interventions for Smoking Cessation: An Overview and Network Meta-Analysis. Cochrane Database of Systematic Reviews 2013, Issue 5. A rt. No.: CD009329. DOI: 0.1002/14651858.CD009329.pub2.
- 4. Food and Drug Administration. Modifications to Labeling of Nicotine Replacement Therapy Products for Over-The-Counter Human Use. Docket No. FDA-2013-N-0341. Federal Register Vol 78, No. 63, April 2, 2013.
- Food and Drug Administration. June 22, 2015. Consumer Updates. Nicotine Replacement Therapy Labels May Change. Retrieved November 23, 2015 from <a href="http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm345087.htm">http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm345087.htm</a>
- 6. Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis. 2010;8:8. DOI: 10.1186/1617-9625-8-8.
- 7. Varenicline http://labeling.pfizer.com/ShowLabeling.aspx?id=557. NY, NY: Pfizer; 2015.
- 8. Bupropion <a href="https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing\_Information/Zyban/pdf/ZYBAN-PI-MG.PDF">https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing\_Information/Zyban/pdf/ZYBAN-PI-MG.PDF</a>. Research Triangle Park, NC: GlaxoSmithKline; 2014.
- 9. Information for Healthcare Professionals: Varenicline (marketed at Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics). FDA Alert [7/1/2009]. Federal Drug Adminstration. Last updated 8/15/2013. Retrieved December 2, 2015
- 10. Blondal T et al. Nicotine Nasal Spray with Nicotine Patch for Smoking Cessation: Randomized Trial with Six Year Follow-Up. BMJ 1999;318:285-9.
- 11. Bohadana A et al. Nicotine Inhaler and Nicotine Patch as a Combination Therapy for Smoking Cessation: A Randomized, Double-Blind, Placebo-Controlled Trial. Arch Intern Med 2000;160:3128-34.
- 12. Jorenby D et al. A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation. NEJM 1999;340:685-91.
- 13. Piper ME et al. A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation Pharmacotherapies. Arch Gen Psychiatry 2009;66(11):1253-62.
- 14. Smith SS et al. Comparative Effectiveness of 5 Smoking Cessation Pharmacotherapies in Primary Care Clinics. Arch Intern Med 2009;169(22):2148-55.
- 15. Kornitzer M et al. Combined Use of Nicotine Patch and Gum in Smoking Cessation: A Placebo-Controlled Clinical Trial. Prev Med 1995;24:41-7.

